We represented BioMatrix Specialty Pharmacy, a comprehensive, nationwide specialty pharmacy services and digital health technology solutions provider, in its acquisition of City Drugs, a New York City-based specialty pharmacy that specializes in the treatment of complex medical conditions including hepatitis, oncology, auto-immune diseases, and gastroenterology. Terms of the transaction were not disclosed.
BioMatrix Acquires City Drugs
You Also May Be Interested In:
Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers
Representation of Lead Capital Partners, a multi-family sponsored private equity firm, in its acquisition of Ladd Dental Group, Inc., a dental service provider with six locations throughout central Indiana
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.